<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="7e5ae919-bb2d-4b73-9c2d-0fe1a367c17e"/>
   <code code="34391-3" displayName="HUMAN PRESCRIPTION DRUG LABEL" codeSystem="2.16.840.1.113883.6.1"/>
   <title>
      <content styleCode="bold">These highlights do not include all the information needed to use Brimonidine tartrate ophthalmic solution </content>
      <content styleCode="bold">0.1% and </content>
      <content styleCode="bold">0.15% safely and effectively.  See full prescribing information for brimonidine tartrate ophthalmic solution</content>
      <content styleCode="bold"> 0.1% and</content>
      <content styleCode="bold"> 0.15%.  </content>
      <br/>
      <content styleCode="bold">     </content>
      <br/>
      <content styleCode="bold">Brimonidine tartrate ophthalmic solution </content>
      <content styleCode="bold">0.1% and </content>
      <content styleCode="bold">0.15%</content>
      <br/>
      <content styleCode="bold">Initial U.S. Approval:</content>
      <content styleCode="bold"> 1996 </content>
      <br/>
   </title>
   <effectiveTime value="20250321"/>
   <setId root="5c4aea88-95ca-4da8-a3da-02f10c8b6623"/>
   <versionNumber value="9"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="877645267" root="1.3.6.1.4.1.519.1"/>
            <name>Pacific Pharma, Inc.</name>
            <assignedEntity>
               <assignedOrganization/>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="d3e8e6a3-2b3a-4d4e-bc71-cf66b2ecbbe2"/>
               <code code="48780-1" displayName="SPL listing data elements section" codeSystem="2.16.840.1.113883.6.1"/>
               <effectiveTime value="20250325"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="82182-773" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Brimonidine tartrate</name>
                        <formCode code="C60992" displayName="SOLUTION/ DROPS" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>brimonidine tartrate</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="1.5"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="4S9CL2DY2H" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>BRIMONIDINE TARTRATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="E6GNX3HHTE" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>BRIMONIDINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="K679OBS311" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CARBOXYMETHYLCELLULOSE SODIUM, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="91MBZ8H3QO" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM BORATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="R57ZHV85D4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>BORIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM CHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="660YQ98I10" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POTASSIUM CHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="M4I0D6VV5M" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CALCIUM CHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="02F3473H9O" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM CHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="G538EBV4VF" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM CHLORITE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROCHLORIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="5"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43171" displayName="BOTTLE, DROPPER" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="82182-773-05" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" displayName="CARTON" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20220228"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="10"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43171" displayName="BOTTLE, DROPPER" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="82182-773-10" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" displayName="CARTON" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20220228"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="15"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43171" displayName="BOTTLE, DROPPER" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="82182-773-15" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" displayName="CARTON" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20220228"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA021262" root="2.16.840.1.113883.3.150"/>
                           <code code="C73605" displayName="NDA authorized generic" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20220228"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38287" displayName="OPHTHALMIC" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="82182-321" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Brimonidine tartrate</name>
                        <formCode code="C60992" displayName="SOLUTION/ DROPS" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>brimonidine tartrate</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="1"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="4S9CL2DY2H" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>BRIMONIDINE TARTRATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="E6GNX3HHTE" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>BRIMONIDINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="K679OBS311" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CARBOXYMETHYLCELLULOSE SODIUM, UNSPECIFIED FORM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="91MBZ8H3QO" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM BORATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="R57ZHV85D4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>BORIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM CHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="660YQ98I10" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POTASSIUM CHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="M4I0D6VV5M" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CALCIUM CHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="02F3473H9O" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM CHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="G538EBV4VF" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM CHLORITE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROCHLORIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="5"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43171" displayName="BOTTLE, DROPPER" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="82182-321-05" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" displayName="CARTON" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20240102"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="10"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43171" displayName="BOTTLE, DROPPER" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="82182-321-10" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" displayName="CARTON" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20240102"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="15"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43171" displayName="BOTTLE, DROPPER" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="82182-321-15" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" displayName="CARTON" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20240102"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA021770" root="2.16.840.1.113883.3.150"/>
                           <code code="C73605" displayName="NDA authorized generic" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20240102"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38287" displayName="OPHTHALMIC" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section>
               <id root="bd5e6576-003b-45b7-944a-f0974e2a4083"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="43683-2" displayName="RECENT MAJOR CHANGES SECTION"/>
               <effectiveTime value="20250321"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Warnings and Precautions (<linkHtml href="#_5_3_Contamination_of">5.3</linkHtml>)
		     
	
		     
	
		     
	
		     
	3/2025</paragraph>
                        <paragraph>
                           <content styleCode="bold"> </content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="_1_Indications_and">
               <id root="d12abfa0-37b2-41af-a2ff-5cba07b76a8b"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34067-9" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>
                  <content styleCode="bold">1</content>
                  <content styleCode="bold">
		     
	INDICATIONS AND USAGE</content>
               </title>
               <text>
                  <paragraph>Brimonidine tartrate ophthalmic solution 0.1% or 0.15% is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. </paragraph>
               </text>
               <effectiveTime value="20250321"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Brimonidine tartrate ophthalmic solution 0.1% or 0.15%<content styleCode="bold">
                              <sup> </sup>
                           </content>is an alpha adrenergic agonist indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. (<content styleCode="bold">
                              <linkHtml href="#_1_Indications_and">1</linkHtml>
                           </content>) </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="_2_Dosage_and">
               <id root="dfea5916-f80c-4dd1-a5ac-fa7a714851df"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34068-7" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>
                  <content styleCode="bold">2</content>
                  <content styleCode="bold">
		     
	DOSAGE AND ADMINISTRATION</content>
               </title>
               <text>
                  <paragraph>The recommended dosage is one drop of brimonidine tartrate ophthalmic solution 0.1% or 0.15% in the affected eye(s) three times daily, approximately 8 hours apart. Brimonidine tartrate ophthalmic solution 0.1% or 0.15% may be used concomitantly with other topical ophthalmic drug products to lower intraocular pressure. If more than one topical ophthalmic product is to be used, the different products should be instilled at least 5 minutes apart. </paragraph>
               </text>
               <effectiveTime value="20250321"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>One drop in the affected eye(s) three times daily, approximately 8 hours apart. (<content styleCode="bold">
                              <linkHtml href="#_2_Dosage_and">2</linkHtml>
                           </content>)  </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="_3_Dosage_Forms">
               <id root="551e1060-a21c-42e1-b271-9589baeb9ff7"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="43678-2" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>
                  <content styleCode="bold">3</content>
                  <content styleCode="bold">
		     
	DOSAGE FORMS AND STRENGTHS</content>
               </title>
               <text>
                  <paragraph>Ophthalmic solution containing 0.1% (1 mg/mL) or 0.15% (1.5 mg/mL) brimonidine tartrate. </paragraph>
               </text>
               <effectiveTime value="20250321"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Ophthalmic solution containing 0.1% (1 mg/mL) or 0.15% (1.5 mg/mL) brimonidine tartrate. (<content styleCode="bold">
                              <linkHtml href="#_3_Dosage_Forms">3</linkHtml>
                           </content>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section>
               <id root="1333f576-98a7-41d8-a27c-8cadd34ab70f"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34070-3" displayName="CONTRAINDICATIONS SECTION"/>
               <title>
                  <content styleCode="bold">4</content>
                  <content styleCode="bold">
		     
	CONTRAINDICATIONS</content>
               </title>
               <effectiveTime value="20250321"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Neonates and infants  (pediatric patients younger than 2 years old). (<content styleCode="bold">
                                 <linkHtml href="#_4_1_Neonates_and">4.1</linkHtml>
                              </content>)<br/>
                           </item>
                           <item>Hypersensitivity Reactions. (<linkHtml href="#_4_2_Hypersensitivity_Reactions">4.2</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="_4_1_Neonates_and">
                     <id root="4932a47f-15d9-4bb9-b08d-5a7abe4ce26b"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">4.1</content>
                        <content styleCode="bold">
		     
	Neonates and Infants (</content>
                        <content styleCode="bold">Pediatric Patients Younger than 2 Years Old</content>
                        <content styleCode="bold">)</content>
                     </title>
                     <text>
                        <paragraph>Brimonidine tartrate ophthalmic solution 0.1% and 0.15% is contraindicated in neonates and infants (pediatric patients younger than 2 years old) <content styleCode="italics">[see Use in Specific Populations (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_8_4_Pediatric_Use">8.4</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
               <component>
                  <section ID="_4_2_Hypersensitivity_Reactions">
                     <id root="1f1de92c-07b5-4264-9f53-ec33bd9879c1"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">4.2</content>
                        <content styleCode="bold">
		     
	Hypersensitivity Reactions</content>
                     </title>
                     <text>
                        <paragraph>Brimonidine tartrate ophthalmic solution 0.1% and 0.15% is contraindicated in patients who have exhibited a hypersensitivity reaction to any component of this medication in the past. </paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="76cdb116-200c-470c-9560-adae28ac48b1"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="43685-7" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>
                  <content styleCode="bold">5</content>
                  <content styleCode="bold">
		     
	WARNINGS AND PRECAUTIONS</content>
               </title>
               <effectiveTime value="20250321"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Potentiation of vascular insufficiency. (<content styleCode="bold">
                              <linkHtml href="#_5_1_Potentiation_of">5.1</linkHtml>
                           </content>)
		     
	</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="_5_1_Potentiation_of">
                     <id root="e2e3b32f-4fa1-41e4-8dfa-b08d6a471167"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.1</content>
                        <content styleCode="bold">
		     
	Potentiation of Vascular Insufficiency</content>
                     </title>
                     <text>
                        <paragraph>Brimonidine tartrate ophthalmic solution 0.1% and 0.15% may potentiate syndromes associated with vascular insufficiency. Brimonidine tartrate ophthalmic solution 0.1% and 0.15% should be used with caution in patients with depression, cerebral or coronary insufficiency, Raynaud’s phenomenon, orthostatic hypotension, or thromboangiitis obliterans. </paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
               <component>
                  <section ID="_5_2_Severe_Cardiovascular">
                     <id root="7d0daaf3-57f4-4017-83b7-4d40460de9ac"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.2</content>
		     
	<content styleCode="bold">Severe </content>
                        <content styleCode="bold">C</content>
                        <content styleCode="bold">ardiovascular Disease</content>
                     </title>
                     <text>
                        <paragraph>Although brimonidine tartrate ophthalmic solution had minimal effect on the blood pressure of patients in clinical studies, caution should be exercised in treating patients with severe cardiovascular disease.</paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
               <component>
                  <section ID="_5_3_Contamination_of">
                     <id root="ff5224be-c698-407a-82aa-5f0facfc813e"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.3</content>
                        <content styleCode="bold">
		     
	Contamination of Topical Ophthalmic Products After Use</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products. These containers had been inadvertently contaminated by patients who, in most cases, had a concurrent corneal disease or a disruption of the ocular epithelial surface. Do not touch the tip of the dispensing container to the eye or surrounding structures. Serious damage to the eye and subsequent loss of vision may result from using contaminated solutions <content styleCode="italics">[</content>
                              <content styleCode="italics">see </content>
                              <content styleCode="italics">Patient Counseling Information (</content>
                              <content styleCode="bold italics">
                                 <linkHtml href="#_17_Patient_Counseling">17</linkHtml>
                              </content>
                              <content styleCode="italics">)]</content>. </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="a6f973ac-5e97-4eba-aac0-4a420085ccdc"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34084-4" displayName="ADVERSE REACTIONS SECTION"/>
               <title>
                  <content styleCode="bold">6</content>
                  <content styleCode="bold">
		     
	ADVERSE REACTIONS</content>
               </title>
               <text>
                  <paragraph>The following serious adverse reactions are described elsewhere in the labeling:</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Potentiation of Vascular Insufficiency <content styleCode="italics">[</content>
                        <content styleCode="italics">see Warnings and Precautions (</content>
                        <content styleCode="italics">
                           <linkHtml href="#_5_1_Potentiation_of">5.1</linkHtml>
                        </content>
                        <content styleCode="italics">)</content>
                        <content styleCode="italics">]</content>
                        <br/>
                     </item>
                     <item>Severe Cardiovascular Disease <content styleCode="italics">[</content>
                        <content styleCode="italics">see Warnings and Precautions (</content>
                        <content styleCode="italics">
                           <linkHtml href="#_5_2_Severe_Cardiovascular">5.2</linkHtml>
                        </content>
                        <content styleCode="italics">)</content>
                        <content styleCode="italics">]</content>
                        <br/>
                     </item>
                     <item>Contamination of Topical Ophthalmic Products after Use <content styleCode="italics">[</content>
                        <content styleCode="italics">see Warnings and Precautions (</content>
                        <content styleCode="italics">
                           <linkHtml href="#_5_3_Contamination_of">5.3</linkHtml>
                        </content>
                        <content styleCode="italics">)</content>
                        <content styleCode="italics">]</content>
                        <br/>
                     </item>
                     <item>Neonates and Infants (Pediatric Patients Younger than 2 Years Old) <content styleCode="italics">[</content>
                        <content styleCode="italics">see Contraindications (</content>
                        <content styleCode="italics">
                           <linkHtml href="#_4_1_Neonates_and">4.1</linkHtml>
                        </content>
                        <content styleCode="italics">)</content>
                        <content styleCode="italics">]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20250321"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Most common adverse reactions occurring in approximately 5% to 20% of patients receiving brimonidine ophthalmic solution (0.1% to 0.2%) included allergic conjunctivitis, burning sensation, conjunctival folliculosis, conjunctival hyperemia, eye pruritus, hypertension, ocular allergic reaction, oral dryness, and visual disturbance. (<content styleCode="bold">
                              <linkHtml href="#_6_1_Clinical_Studies">6.1</linkHtml>
                           </content>)</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <br/>
                              <br/>To report SUSPECTED ADVERSE REACTIONS, contact AbbVie at 1-800-678-1605 or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="_6_1_Clinical_Studies">
                     <id root="6c07ed9c-5371-4e01-a336-95e29c954f92"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="90374-0" displayName="CLINICAL TRIALS EXPERIENCE SECTION"/>
                     <title>
                        <content styleCode="bold">6.1</content>
                        <content styleCode="bold">
		     
	Clinical </content>
                        <content styleCode="bold"> Trials </content>
                        <content styleCode="bold">Experience</content>
                     </title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>Adverse reactions occurring in approximately 10% to 20% of the subjects receiving brimonidine ophthalmic solution (0.1% to 0.2%) included: allergic conjunctivitis, conjunctival hyperemia, and eye pruritus. Adverse reactions occurring in approximately 5% to 9% included: burning sensation, conjunctival folliculosis, hypertension, ocular allergic reaction, oral dryness, and visual disturbance. </paragraph>
                        <paragraph>Adverse reactions occurring in approximately 1% to 4% of the subjects receiving brimonidine ophthalmic solution (0.1% to 0.2%) included: abnormal taste, allergic reaction, asthenia, blepharitis, blepharoconjunctivitis, blurred vision, bronchitis, cataract, conjunctival edema, conjunctival hemorrhage, conjunctivitis, cough, dizziness, dyspepsia, dyspnea, epiphora, eye discharge, eye dryness, eye irritation, eye pain, eyelid edema, eyelid erythema, fatigue, flu syndrome, follicular conjunctivitis, foreign body sensation, gastrointestinal disorder, headache, hypercholesterolemia, hypotension, infection (primarily colds and respiratory infections), insomnia, keratitis, lid disorder, pharyngitis, photophobia, rash, rhinitis, sinus infection, sinusitis, somnolence, stinging, superficial punctate keratopathy, tearing, visual field defect, vitreous detachment, vitreous disorder, vitreous floaters, and worsened visual acuity.</paragraph>
                        <paragraph>The following reactions were reported in less than 1% of subjects: corneal erosion, hordeolum, nasal dryness, and taste perversion.</paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="12850e04-741a-4957-aca2-5cbd4ab9835e"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="90375-7" displayName="POSTMARKETING EXPERIENCE SECTION"/>
                     <title>
                        <content styleCode="bold">6.2</content>
                        <content styleCode="bold">
		     
	Postmarketing Experience</content>
                     </title>
                     <text>
                        <paragraph>The following reactions have been identified during postapproval use of brimonidine tartrate ophthalmic solutions. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Bradycardia, depression, hypersensitivity, iritis, keratoconjunctivitis sicca, miosis, nausea, skin reactions (including erythema, eyelid pruritus, rash, and vasodilation), syncope, and tachycardia.<br/>
                           </item>
                           <item>Apnea, coma, hypotension, hypothermia, hypotonia, lethargy, pallor, respiratory depression, and somnolence have been reported in infants receiving brimonidine tartrate ophthalmic solutions. </item>
                        </list>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="25ca9f85-a09c-4829-a89e-1133afb47e61"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34073-7" displayName="DRUG INTERACTIONS SECTION"/>
               <title>
                  <content styleCode="bold">7</content>
                  <content styleCode="bold">
		     
	DRUG INTERACTIONS</content>
               </title>
               <effectiveTime value="20250321"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Antihypertensives/cardiac glycosides may lower blood pressure. (<content styleCode="bold">
                                 <linkHtml href="#_7_1_Antihypertensives_Cardiac_Glyco">7.1</linkHtml>
                              </content>)<br/>
                           </item>
                           <item>Use with CNS depressants may result in an additive or potentiating effect. (<content styleCode="bold">
                                 <linkHtml href="#_7_2_CNS_Depressants">7.2</linkHtml>
                              </content>)<br/>
                           </item>
                           <item>Tricyclic antidepressants may potentially blunt the hypotensive effect of systemic clonidine. (<content styleCode="bold">
                                 <linkHtml href="#_7_3_Tricyclic_Antidepressants">7.3</linkHtml>
                              </content>)<br/>
                           </item>
                           <item>Monoamine oxidase inhibitors may result in increased hypotension. (<content styleCode="bold">
                                 <linkHtml href="#_7_4_Monoamine_Oxidase">7.4</linkHtml>
                              </content>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="_7_1_Antihypertensives_Cardiac_Glyco">
                     <id root="3eca2032-9f58-451e-967e-62afa314dc84"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">7.1</content>
                        <content styleCode="bold">
		     
	Antihypertensives/Cardiac Glycosides</content>
                     </title>
                     <text>
                        <paragraph>Because brimonidine tartrate ophthalmic solution 0.1% and 0.15% may reduce blood pressure, caution in using drugs such as antihypertensives and/or cardiac glycosides with brimonidine tartrate ophthalmic solution 0.1% and 0.15% is advised. </paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
               <component>
                  <section ID="_7_2_CNS_Depressants">
                     <id root="75f507c9-6525-4f26-a3c2-111650b8e89a"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">7.2</content>
                        <content styleCode="bold">
		     
	CNS Depressants</content>
                     </title>
                     <text>
                        <paragraph>Although specific drug interaction studies have not been conducted with brimonidine tartrate ophthalmic solution 0.1% and 0.15%, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, or anesthetics) should be considered. </paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
               <component>
                  <section ID="_7_3_Tricyclic_Antidepressants">
                     <id root="5b8060a6-0df9-46e1-b412-3fa9ddce0afc"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">7.3</content>
                        <content styleCode="bold">
		     
	Tricyclic Antidepressants</content>
                     </title>
                     <text>
                        <paragraph>Tricyclic antidepressants have been reported to blunt the hypotensive effect of systemic clonidine. It is not known whether the concurrent use of these agents with brimonidine tartrate ophthalmic solution 0.1% and 0.15% in humans can lead to resulting interference with the IOP lowering effect. Caution is advised in patients taking tricyclic antidepressants which can affect the metabolism and uptake of circulating amines.</paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
               <component>
                  <section ID="_7_4_Monoamine_Oxidase">
                     <id root="4c5400d5-bd56-4041-ac80-d05e883fc848"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">7.4</content>
                        <content styleCode="bold">
		     
	Monoamine Oxidase Inhibitors</content>
                     </title>
                     <text>
                        <paragraph>Monoamine oxidase (MAO) inhibitors may theoretically interfere with the metabolism of brimonidine and potentially result in an increased systemic side-effect such as hypotension. Caution is advised in patients taking MAO inhibitors which can affect the metabolism and uptake of circulating amines.</paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="773dc687-665f-46a8-8d3c-50924f45c912"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="43684-0" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>
                  <content styleCode="bold">8</content>
                  <content styleCode="bold">
		     
	USE IN SPECIFIC POPULATIONS</content>
               </title>
               <effectiveTime value="20250321"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Use with caution in  pediatric patients aged 2 years and older. (<content styleCode="bold">
                              <linkHtml href="#_8_4_Pediatric_Use">8.4</linkHtml>
                           </content>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section>
                     <id root="fa0b1a46-48d6-4a45-953b-22dd8e44eb47"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42228-7" displayName="PREGNANCY SECTION"/>
                     <title>
                        <content styleCode="bold">8.1</content>
                        <content styleCode="bold">
		     
	Pregnancy</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>There are no adequate and well-controlled studies with brimonidine tartrate ophthalmic solution 0.1% and 0.15% in pregnant women.  In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.</paragraph>
                        <paragraph>In animal studies, brimonidine crossed the placenta and entered into the fetal circulation to a limited extent <content styleCode="italics">(see Data</content>
                           <content styleCode="italics">)</content>. Because animal reproduction studies are not always predictive of human response, brimonidine tartrate ophthalmic solution 0.1% and 0.15% should be used during pregnancy only if the potential benefit to the mother justifies the potential risk to the fetus. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Data </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Human Data</content>
                        </paragraph>
                        <paragraph>Limited available data from postmarketing safety reports and published literature with topical use of brimonidine ophthalmic solution in pregnant women are insufficient to inform a drug-associated risk of pregnancy-related adverse outcomes including miscarriage, stillbirth, congenital anomaly, and events experienced by offspring while breastfeeding.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Animal Data</content>
                        </paragraph>
                        <paragraph>Embryofetal studies were conducted in pregnant rabbits administered brimonidine tartrate by daily oral gavage on gestation days 6 to 18, to target the period of organogenesis. Brimonidine caused miscarriage at 5 mg/kg/day (approximately 70- or 50-times the recommended human ophthalmic dose [RHOD] based on AUC, respectively for brimonidine tartrate 0.1% and 0.15%). The no observed adverse effect level (NOAEL) for developmental toxicity in rabbits was 1 mg/kg/day (approximately 9- and 6-fold the RHOD based on AUC, respectively for brimonidine tartrate 0.1% and 0.15%). No treatment-related malformations were observed in rabbits. Signs of maternal sedation and fatigue were observed at all dose levels; the lowest observed adverse effect level (LOAEL) for maternal toxicity was 5 mg/kg/day, based on the dose response for these signs.</paragraph>
                        <paragraph>Embryofetal studies were conducted in pregnant rats administered brimonidine tartrate by daily oral gavage on gestation days 6 to 15, to target the period of organogenesis. The NOAEL for developmental toxicity was 2.5 mg/kg/day (approximately 1100- and 750-fold the RHOD based on AUC, respectively for brimonidine tartrate 0.1% and 0.15%). No treatment-related malformations were observed in rats. The LOAEL for maternal toxicity was 2.5 mg/kg/day, based on signs of sedation and fatigue. The maternal NOAEL was 1.0 mg/kg/day (250- and 180-fold the RHOD based on AUC, respectively for brimonidine tartrate 0.1% and 0.15%).</paragraph>
                        <paragraph>After pregnant rats received a single oral dose of <sup>14</sup>C-brimonidine tartrate, brimonidine and metabolites crossed the placenta and were detectable in fetal blood and organs.</paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="80aea606-bcec-48e7-8616-718d2343c9ce"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="77290-5" displayName="LACTATION SECTION"/>
                     <title>
                        <content styleCode="bold">8.</content>
                        <content styleCode="bold">2</content>
		     
	<content styleCode="bold">Lactation</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>It is not known whether brimonidine tartrate is excreted in human milk. In animal studies, brimonidine tartrate has been shown to cross the blood-brain barrier and is excreted into breast milk after oral administration to lactating rats <content styleCode="italics">(</content>
                           <content styleCode="italics">see Data</content>
                           <content styleCode="italics">)</content>. Because of the potential for serious adverse reactions, including central nervous system depression and apnea, from brimonidine tartrate ophthalmic solution 0.1% and 0.15% in nursing infants, brimonidine tartrate ophthalmic solution 0.1% and 0.15% is not recommended for use during lactation. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Data </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Animal Data</content>
                        </paragraph>
                        <paragraph>After a single oral dose of <sup>14</sup>C-labeled brimonidine tartrate to lactating rats, brimonidine and metabolites were detected in milk. After male and female rats received a single oral dose of <sup>14</sup>C-brimonidine tartrate, brimonidine crossed the blood-brain barrier. Radiolabel was detected in the cerebellum, cerebrum, and spinal cord.</paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
               <component>
                  <section ID="_8_4_Pediatric_Use">
                     <id root="e5f1da05-c578-4aeb-8832-b4175cfe80a9"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="34081-0" displayName="PEDIATRIC USE SECTION"/>
                     <title>
                        <content styleCode="bold">8.4</content>
                        <content styleCode="bold">
		     
	Pediatric Use</content>
                     </title>
                     <text>
                        <paragraph>Brimonidine tartrate ophthalmic solution 0.1% and 0.15% is contraindicated in pediatric patients younger than 2 years old <content styleCode="italics">[</content>
                           <content styleCode="italics">see Contraindications (</content>
                           <content styleCode="bold italics">
                              <linkHtml href="#_4_1_Neonates_and">4.1</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>. During postmarketing surveillance, apnea, bradycardia, coma, hypotension, hypothermia, hypotonia, lethargy, pallor, respiratory depression, and somnolence have been reported in infants receiving brimonidine. </paragraph>
                        <paragraph>In a well-controlled clinical study conducted in pediatric glaucoma patients aged 2 to 7 years old) the most commonly observed adverse reactions with brimonidine tartrate ophthalmic solution 0.2% dosed three times daily were somnolence (50% to 83% in patients aged 2 to 6 years old) and decreased alertness.  In pediatric patients aged 7 years and older (greater than 20 kg), somnolence appears to occur less frequently (25%).  Approximately 16% of pediatric patients on brimonidine tartrate ophthalmic solution 0.2% discontinued from the study due to somnolence.<content styleCode="bold"> </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="d3bd6bbe-d07c-4352-bd66-6d03b7b1ff28"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="34082-8" displayName="GERIATRIC USE SECTION"/>
                     <title>
                        <content styleCode="bold">8.5</content>
                        <content styleCode="bold">
		     
	Geriatric Use</content>
                     </title>
                     <text>
                        <paragraph>No overall differences in safety or effectiveness have been observed between elderly and other adult patients.</paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="f2af2a22-a89b-4432-b211-bc6debfbd28b"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34088-5" displayName="OVERDOSAGE SECTION"/>
               <title>
                  <content styleCode="bold">10</content>
                  <content styleCode="bold">
		     
	OVERDOSAGE</content>
               </title>
               <text>
                  <paragraph>Limited information exists on accidental ingestion of brimonidine in adults; the only adverse reaction reported to date has been hypotension. Symptoms of brimonidine overdose have been reported in neonates, infants, and children receiving brimonidine tartrate ophthalmic solution 0.1% and 0.15% as part of medical treatment of congenital glaucoma or by accidental oral ingestion <content styleCode="italics">[see Use in Specific Populations (</content>
                     <content styleCode="bold italics">
                        <linkHtml href="#_8_4_Pediatric_Use">8.4</linkHtml>
                     </content>
                     <content styleCode="italics">)]</content>
                     <content styleCode="italics">.</content> Treatment of an oral overdose includes supportive and symptomatic therapy; a patent airway should be maintained. </paragraph>
               </text>
               <effectiveTime value="20250321"/>
            </section>
         </component>
         <component>
            <section>
               <id root="ec714d7e-ce71-4f96-89d2-9cfe263a9dcd"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34089-3" displayName="DESCRIPTION SECTION"/>
               <title>
                  <content styleCode="bold">11</content>
                  <content styleCode="bold">
		     
	DESCRIPTION</content>
               </title>
               <text>
                  <paragraph>Brimonidine tartrate ophthalmic solution 0.1% or 0.15%, sterile, is a relatively selective alpha-2 adrenergic receptor agonist for topical ophthalmic use.  </paragraph>
                  <paragraph>The structural formula of brimonidine tartrate is:</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM02000001"/>
                  </paragraph>
                  <paragraph>5-Bromo-6-(2-imidazolidinylideneamino) quinoxaline L-tartrate; MW= 442.24</paragraph>
                  <paragraph>In solution, brimonidine tartrate ophthalmic solution 0.1% and 0.15% has a clear, greenish-yellow color. It has an osmolality of 250-350 mOsmol/kg and a pH of 7.4-8.0 (0.1%) or 6.9-7.4 (0.15%).</paragraph>
                  <paragraph>Brimonidine tartrate appears as an off-white to pale-yellow powder and is soluble in both water (0.6 mg/mL) and in the product vehicle (1.4 mg/mL) at pH 7.7. </paragraph>
                  <paragraph>Each mL of brimonidine tartrate ophthalmic solution 0.1% and 0.15% contains the active ingredient brimonidine tartrate 0.1% (1 mg/mL) or 0.15% (1.5 mg/mL) with the inactive ingredients sodium carboxymethylcellulose; sodium borate; boric acid; sodium chloride; potassium chloride; calcium chloride; magnesium chloride; PURITE<sup>®</sup> 0.005% (0.05 mg/mL) as a preservative; purified water; and hydrochloric acid and/or sodium hydroxide to adjust pH.</paragraph>
               </text>
               <effectiveTime value="20250321"/>
               <component>
                  <observationMedia ID="MM02000001">
                     <text>The structural formula of brimonidine tartrate.</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="brimonidine-tartrate-ag-0-1-0-15-ophthalmic-soluti-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="5eb92f20-050c-43b6-ba6f-2ca7703590bb"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34090-1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>
                  <content styleCode="bold">12</content>
                  <content styleCode="bold">
		     
	CLINICAL PHARMACOLOGY</content>
               </title>
               <effectiveTime value="20250321"/>
               <component>
                  <section>
                     <id root="39b4f9b7-6cfc-4c19-9503-e76c0ef03388"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="43679-0" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>
                        <content styleCode="bold">12.1</content>
                        <content styleCode="bold">
		     
	Mechanism of Action </content>
                     </title>
                     <text>
                        <paragraph>Brimonidine tartrate ophthalmic solution 0.1% and 0.15% is a relatively selective alpha-2 adrenergic receptor agonist with a peak ocular hypotensive effect occurring at two hours post-dosing.</paragraph>
                        <paragraph>Fluorophotometric studies in animals and humans suggest that brimonidine tartrate has a dual mechanism of action by reducing aqueous humor production and increasing uveoscleral outflow. </paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="21bf7bb7-b494-4eec-9088-0d08088a68e0"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="43682-4" displayName="PHARMACOKINETICS SECTION"/>
                     <title>
                        <content styleCode="bold">12.3</content>
                        <content styleCode="bold">
		     
	Pharmacokinetics</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Absorption</content>
                        </paragraph>
                        <paragraph>After ocular administration of either a 0.1% or 0.2% solution, plasma concentrations peaked within 0.5 to 2.5 hours and declined with a systemic half-life of approximately 2 hours.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Distribution</content>
                        </paragraph>
                        <paragraph>Brimonidine was approximately 29% bound to plasma proteins in healthy subjects.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Elimination</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Metabolism</content>
                        </paragraph>
                        <paragraph>In humans, brimonidine is extensively metabolized by the liver. </paragraph>
                        <paragraph>
                           <content styleCode="italics">Excretion</content>
                        </paragraph>
                        <paragraph>Urinary excretion is the major route of elimination of brimonidine and its metabolites. Approximately 87% of an orally-administered radioactive dose of brimonidine was eliminated within 120 hours, with 74% found in the urine.  </paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="532725a4-3333-4297-baf5-d25eadb09ec2"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="43680-8" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>
                  <content styleCode="bold">13</content>
                  <content styleCode="bold">
		     
	NONCLINICAL TOXICOLOGY</content>
               </title>
               <effectiveTime value="20250321"/>
               <component>
                  <section>
                     <id root="722a0736-238e-4eaa-87d6-a6c4eac40462"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="34083-6" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>
                        <content styleCode="bold">13.1</content>
                        <content styleCode="bold">
		     
	Carcinogenesis, Mutagenesis, Impairment of Fertility</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Carcinogenesis</content>
                        </paragraph>
                        <paragraph>No compound-related carcinogenic effects were observed in either mice or rats following a 21-month and 24-month study, respectively. In these studies, dietary administration of brimonidine tartrate at doses up to 2.5 mg/kg/day in mice and 1 mg/kg/day in rats achieved approximately 150 and 120 times or 93 and 76 times the recommended human ophthalmic dose (RHOD) based on C<sub>max</sub> respectively for brimonidine tartrate 0.1% or 0.15%.  </paragraph>
                        <paragraph>
                           <content styleCode="underline">Mutagenesis</content>
                        </paragraph>
                        <paragraph>Brimonidine tartrate was not mutagenic or clastogenic in a series of <content styleCode="italics">in vitro</content> and <content styleCode="italics">in vivo</content> studies including the Ames bacterial reversion test, chromosomal aberration assay in Chinese Hamster Ovary (CHO) cells, and three <content styleCode="italics">in vivo</content> studies in CD-1 mice: a host-mediated assay, cytogenetic study, and dominant lethal assay. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Impairment of Fertility</content>
                        </paragraph>
                        <paragraph>A reproduction and fertility study in rats with brimonidine tartrate demonstrated no adverse effect on male or female fertility at oral doses up to 1mg/kg (approximately 250 or 180 times the recommended human ophthalmic dose [RHOD] based on estimated AUC) respectively for brimonidine tartrate 0.1% and 0.15%. </paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="730d4364-d2b8-44a3-aa2c-50ee618887e7"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34092-7" displayName="CLINICAL STUDIES SECTION"/>
               <title>
                  <content styleCode="bold">14</content>
                  <content styleCode="bold">
		     
	CLINICAL STUDIES</content>
               </title>
               <text>
                  <paragraph>Elevated IOP presents a major risk factor in glaucomatous field loss. The higher the level of IOP, the greater the likelihood of optic nerve damage and visual field loss. Brimonidine tartrate<sup> </sup>has the action of lowering intraocular pressure with minimal effect on cardiovascular and pulmonary parameters.</paragraph>
                  <paragraph>Clinical studies were conducted to evaluate the safety, efficacy, and acceptability of brimonidine tartrate ophthalmic solution 0.15% compared with brimonidine tartrate ophthalmic solution 0.2% administered three-times-daily in patients with open-angle glaucoma or ocular hypertension. Those results indicated that brimonidine tartrate ophthalmic solution 0.15% is comparable in IOP lowering effect to brimonidine tartrate ophthalmic solution 0.2%, and effectively lowers IOP in patients with open-angle glaucoma or ocular hypertension by approximately 2-6 mmHg.</paragraph>
                  <paragraph>A clinical study was conducted to evaluate the safety, efficacy, and acceptability of brimonidine tartrate ophthalmic solution 0.1% compared with brimonidine tartrate ophthalmic solution 0.2% administered three-times-daily in patients with open-angle glaucoma or ocular hypertension. Those results indicated that brimonidine tartrate ophthalmic solution 0.1% is equivalent in IOP lowering effect to brimonidine tartrate ophthalmic solution 0.2%, and effectively lowers IOP in patients with open-angle glaucoma or ocular hypertension by approximately 2-6 mmHg.</paragraph>
               </text>
               <effectiveTime value="20250321"/>
            </section>
         </component>
         <component>
            <section>
               <id root="881eca9b-d0ce-4ef7-8ccc-3098ec4b279b"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34069-5" displayName="HOW SUPPLIED SECTION"/>
               <title>
                  <content styleCode="bold">16</content>
                  <content styleCode="bold">
		     
	HOW SUPPLIED/STORAGE AND HANDLING</content>
               </title>
               <text>
                  <paragraph>Brimonidine tartrate ophthalmic solution 0.1% and 0.15% is supplied sterile, in teal opaque plastic LDPE bottles and tips, with purple high impact polystyrene (HIPS) caps as follows:</paragraph>
                  <paragraph>
                     <content styleCode="bold">0.1%</content>
                  </paragraph>
                  <paragraph>5 mL in 10 mL bottle         NDC 82182-321-05<br/>10 mL in 10 mL bottle
		     
	NDC 82182-321-10<br/>15 mL in 15 mL bottle
		     
	NDC 82182-321-15</paragraph>
                  <paragraph>
                     <content styleCode="bold">0.15%</content>
                     <br/>5 mL in 10 mL bottle         NDC 82182-773-05<br/>10 mL in 10 mL bottle
		     
	NDC 82182-773-10<br/>15 mL in 15 mL bottle
		     
	NDC 82182-773-15 </paragraph>
                  <paragraph>
                     <content styleCode="bold">Storage: </content>Store at 15<sup>o</sup>C to 25<sup>o</sup>C (59<sup>o</sup>F to 77<sup>o</sup>F). </paragraph>
               </text>
               <effectiveTime value="20250321"/>
            </section>
         </component>
         <component>
            <section ID="_17_Patient_Counseling">
               <id root="75ca76ab-42a1-440a-87c3-f7d85475645c"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34076-0" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>
                  <content styleCode="bold">17</content>
                  <content styleCode="bold">
		     
	PATIENT COUNSELING INFORMATION</content>
               </title>
               <text>
                  <paragraph>
                     <content styleCode="underline">Handling the Container</content>
                  </paragraph>
                  <paragraph>Instruct patients that ocular solutions, if handled improperly or if the tip of the dispensing container contacts the eye or surrounding structures, can become contaminated by common bacteria known to cause ocular infections. Serious damage to the eye and subsequent loss of vision may result from using contaminated solutions <content styleCode="italics">[see Warnings and Precautions (</content>
                     <content styleCode="bold italics">
                        <linkHtml href="#_5_3_Contamination_of">5.3</linkHtml>
                     </content>
                     <content styleCode="italics">)]</content>. Always replace the cap after using. If solution changes color or becomes cloudy, do not use. Do not use the product after the expiration date marked on the bottle.</paragraph>
                  <paragraph>
                     <content styleCode="underline">When to Seek Physician Advice</content>
                  </paragraph>
                  <paragraph>Advise patients that if they have ocular surgery or develop an intercurrent ocular condition (e.g., trauma or infection), they should immediately seek their physician's advice concerning the continued use of the present multidose container. </paragraph>
                  <paragraph>
                     <content styleCode="underline">Use with Other Ophthalmic Drugs</content>
                  </paragraph>
                  <paragraph>Advise patients that if more than one topical ophthalmic drug is being used, the drugs should be administered at least five minutes apart.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Potential for Decreased Mental Alertness</content>
                  </paragraph>
                  <paragraph>As with other similar medications, brimonidine tartrate ophthalmic solution 0.1% and 0.15% may cause fatigue and/or drowsiness in some patients. Caution patients who engage in hazardous activities of the potential for a decrease in mental alertness. </paragraph>
                  <paragraph>Distributed by: <br/>AbbVie Inc.<br/>North Chicago, IL 60064</paragraph>
                  <paragraph>© 2025 AbbVie. All rights reserved.<br/>PACIFIC PHARMA and its design and PURITE are trademarks of Allergan, Inc., an AbbVie company.</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM02000002"/>
                  </paragraph>
                  <paragraph>20091159</paragraph>
               </text>
               <effectiveTime value="20250321"/>
               <component>
                  <observationMedia ID="MM02000002">
                     <text>Pacific Pharma Logo</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="brimonidine-tartrate-ag-0-1-0-15-ophthalmic-soluti-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="8057d56a-5604-4963-8f70-d40635386a16"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="51945-4" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>
                  <content styleCode="bold">PRINCIPAL DISPLAY PANEL</content>
               </title>
               <text>
                  <paragraph>NDC  82182-773-05<br/>PACIFIC<content styleCode="bold">
                        <br/>PHARMA</content>
                     <br/>
                     <content styleCode="bold">BRIMONIDINE</content>
                     <content styleCode="bold">
                        <br/>TARTRATE</content>
                     <br/>
                     <content styleCode="bold">ophthalmic</content>
                     <content styleCode="bold">
                        <br/>solution, </content>
                     <content styleCode="bold">
                        <br/>0.15%</content>
                     <content styleCode="bold">
                        <br/>5 </content>
                     <content styleCode="bold">mL</content>
                     <br/>
                     <content styleCode="bold">sterile</content>
                     <content styleCode="bold">
                        <br/>Rx only</content> <br/>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM02000003"/>
                  </paragraph>
               </text>
               <effectiveTime value="20250321"/>
               <component>
                  <observationMedia ID="MM02000003">
                     <text>NDC  82182-773-05
PACIFIC
PHARMA
BRIMONIDINE
TARTRATE
ophthalmic
solution, 
0.15%
5 mL
sterile
Rx only 


</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="brimonidine-tartrate-ag-0-1-0-15-ophthalmic-soluti-03.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="9047b926-918e-4ac1-bd79-3f0b3036de5f"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="51945-4" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>
                  <content styleCode="bold">PRINCIPAL DISPLAY PANEL</content>
               </title>
               <text>
                  <paragraph>NDC: 82182-321-05<br/>PACIFIC<br/>
                     <content styleCode="bold">PHARMA</content>
                     <br/>
                     <content styleCode="bold">BRIMONIDINE TARTRATE</content>
                     <br/>
                     <content styleCode="bold">ophthalmic</content>
                     <br/>
                     <content styleCode="bold">solution, </content>
                     <br/>
                     <content styleCode="bold">0.1%</content>
                     <br/>
                     <content styleCode="bold">5 </content>
                     <content styleCode="bold">m</content>
                     <content styleCode="bold">L</content>
                     <br/>
                     <content styleCode="bold">s</content>
                     <content styleCode="bold">terile</content>
                     <br/>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM02000004"/>
                  </paragraph>
               </text>
               <effectiveTime value="20250321"/>
               <component>
                  <observationMedia ID="MM02000004">
                     <text>NDC: 82182-321-05
PACIFIC
PHARMA
BRIMONIDINE TARTRATE
ophthalmic
solution, 
0.1%
5 mL
sterile
Rx only
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="brimonidine-tartrate-ag-0-1-0-15-ophthalmic-soluti-04.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>